Your session is about to expire
← Back to Search
ADAMM- RSM Device for Tuberculosis
N/A
Waitlist Available
Led By Giovanni Ferrara, MD
Research Sponsored by University of Alberta
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 month duration per participant
Awards & highlights
No Placebo-Only Group
Summary
This trial tests a wearable device called ADAMM-RSMTM that measures heart rate, breathing rate, temperature, cough, and activity. It targets patients with serious lung diseases like IPF, CF, bronchiectasis, and TB. The device helps doctors monitor these patients' health by sending vital sign data to a secure database. The ADAMM-RSMTM device is an evolution of the ADAM device, which was developed for asthma monitoring in adolescents.
Eligible Conditions
- Tuberculosis
- Cystic Fibrosis
- Bronchiectasis
- PF-ILD
- Lung Transplant
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 6 month duration per participant
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 month duration per participant
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Length of time wearing device (days)
Secondary study objectives
Prediction of respiratory exacerbations- Number of emergency room visits
Prediction of respiratory exacerbations- Number of hospital admissions
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: DeviceExperimental Treatment1 Intervention
All participants will wear the device to assist in determining the feasibility of wearing the device.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ADAMM- RSM Device
2021
N/A
~10
Find a Location
Who is running the clinical trial?
University of AlbertaLead Sponsor
939 Previous Clinical Trials
433,905 Total Patients Enrolled
Giovanni Ferrara, MDPrincipal InvestigatorUniversity of Alberta
1 Previous Clinical Trials
Share this study with friends
Copy Link
Messenger